In December 2020, all Elmiron legal cases alleging eye damage and retinal injury filed in the federal courts were consolidated by means of an Elmiron MDL Order. These Elmiron legal cases are noteworthy as regards the monetary damages aspect of a lawsuit because these Elmiron-related eye problems can lead to vision loss or blindness.
From the Transfer Order issued for In Re: Elmiron [Pentosan Polysulfate Sodium] Products Liability Litigation, MDL Docket No. 2973, we get the following legal information:
After considering the argument of counsel, we find that centralization of these actions in the District of New Jersey will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. The actions involve common factual issues concerning the propensity of Elmiron to cause retinal injuries, notably atypical or pigmentary maculopathy. Several defendants have marketed Elmiron since its approval in 1996. This litigation likely will implicate complex scientific and regulatory issues. Centralization will eliminate duplicative discovery; avoid inconsistent pretrial rulings; and conserve the resources of the parties, their counsel and the judiciary. [Footnote omitted.]
Unlike most pharmaceutical drug injury lawsuits, for these Elmiron legal cases a person does not need to have been using Elmiron at the time when their eye damage or retinal injury was diagnosed by a doctor. This is because there can be a delay, or latency period, from a patient’s Elimiron “exposure” until there is Elmirion “toxicity” causing Elmiron-related eye problems.
If we can be of assistance to you or someone else regarding a possible drug injury lawsuit for Elmiron-related eye problems, you can send can submit an online Elmiron Case Evaluation Form or you can call us on our toll-free number: 800-426-9535.
[View article at original source]